Anavex Life Sciences Corp (AVXL)

[apostrophe]

re: "The company's lead drug candidates comprise ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil, which is in a Phase 2a clinical trial for the treatment of Alzheimer?s and other central nervous system diseases. Its preclinical drug candidates comprise ANAVEX 3-71, which uses ligands that activate sigma-1 receptors to treat Alzheimer?s disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; and ANAVEX 1037 for the treatment of prostate cancer. ..."

With all the focus on Alzheimer's, it's easy to overlook the other potentially valuable IP in the Anavex pipeline. One of my close colleagues was treated for prostate cancer with radiation and medication that gave him "male menopause", a lot of discomfort even after he came back, got very thin. Another co-worker got prostate removed. He survived but also not great. Mention of the other compounds in the newsoracle article with indications for improvement over prostate cancer SOC got my attention. It would be a big improvement over current SOC which centers around cell destruction with attendant collateral damage using radiation and poisons and/or organ removal.

http://www.anavex.com/pipeline/anavex-1037/

ANAVEX 1037

ANAVEX 1037 is designed for the treatment of prostate cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In advanced preclinical studies, this compound revealed antitumor potential with no toxic side effects. It has also been shown to selectively kill human cancer cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific publications describe sigma receptor ligands positively, highlighting the possibility that these ligands may stop tumor growth and induce selective cell death in various tumor cell lines. Sigma receptors are highly expressed in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through tumor cell membrane reorganization and interactions with ion channels, our drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer cells from the original site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation